These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 9337535)
1. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity? Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535 [TBL] [Abstract][Full Text] [Related]
2. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study]. Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457 [TBL] [Abstract][Full Text] [Related]
3. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
4. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer]. Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108 [TBL] [Abstract][Full Text] [Related]
5. [Neuron-specific enolase (NSE) serum level as a prognostic factor in non-small cell lung cancer]. Zych J; Szturmowicz M; Sakowicz A; Słodkowska J; Załeska M; Radzikowska E; Załeska J; Jodkiewicz Z; Rowińska-Zakrzewska E Pneumonol Alergol Pol; 2002; 70(5-6):278-83. PubMed ID: 12518626 [TBL] [Abstract][Full Text] [Related]
6. [Serum neuron specific enolase (NSE) levels in patients with non small cell lung cancer]. Shibayama T; Ohnoshi T; Ueoka H; Horiguchi T; Kodani T; Segawa Y; Maeda T; Miyatake K; Takigawa N; Kimura I Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jun; 30(6):1097-102. PubMed ID: 1324376 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383 [TBL] [Abstract][Full Text] [Related]
8. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma]. Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891 [TBL] [Abstract][Full Text] [Related]
9. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
10. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of serum NSE (neuron specific enolase) levels in cases of small cell lung cancer]. Moriya H; Hisa S; Satoh T; Suzuki S; Kimura K; Higuchi Y; Hoshi K Rinsho Hoshasen; 1988 Jan; 33(1):31-4. PubMed ID: 2835529 [No Abstract] [Full Text] [Related]
12. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544 [TBL] [Abstract][Full Text] [Related]
13. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404 [TBL] [Abstract][Full Text] [Related]
15. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727 [TBL] [Abstract][Full Text] [Related]
16. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]. Pan QR; Zhang X; Xu ZF; Zheng S Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of tumor markers in the management of small cell lung cancer]. Ariyoshi Y Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115 [TBL] [Abstract][Full Text] [Related]
18. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169 [TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Schneider J; Philipp M; Salewski L; Velcovsky HG Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]